TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completion of parent clinical trial for treatment of partial seizures.~Exclusion Criteria:~* Receiving any study drug or experimental device other than lacosamide.~* Meets withdrawal criteria for parent trial or experiencing ongoing serious adverse event.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lacosamide (Type: EXPERIMENTAL): 50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years;~* American Society of Anesthesiologists (ASA) physical status 1-3;~* Scheduled for catheter-based neurointerventional procedures including coiling and stent insertion;~* General anesthesia.~Exclusion Criteria:~* Suspected difficult intubation;~* Neuromuscular disorder;~* Renal impairment creatinine ≥ 2 mg /dl;~* Hepatic dysfunction;~* History of malignant hyperthermia;~* Allergy to neuromuscular blocking drugs, Sugammadex, neostigmine or glycopyrrolate;~* Perioperative respiratory infections and/or pneumonia;~* Intubated or unresponsive;~* Pregnancy or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neostigmine with glycopyrrolate (Type: ACTIVE_COMPARATOR): Neostigmine 0. 07 mg/kg with glycopyrrolate 0.01 mg/kg with ceiling dose of 5 mg neostigmine with 1 mg of glycopyrrolate at the end surgery
- Sugammadex (Type: EXPERIMENTAL): Sugammadex 4 mg/kg at the end surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Dose-response Trial Using rFSH FE 999049 in Women Undergoing IVF/ICSI Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Women diagnosed with tubal infertility, unexplained infertility, infertility related to endometriosis stage I/II or with partners diagnosed with male factor infertility~* Women eligible for IVF (in-vitro fertilisation) and/or ICSI (intracytoplasmic sperm injection) treatment~* Women aged 18-37 years~* Women with body mass index (BMI) of 18.5-32.0 kg/m2~Exclusion Criteria:~* Women with polycystic ovary syndrome (PCOS) associated with anovulation, endometriosis stage III/IV~* Women with history of recurrent miscarriage~* Women with contraindications to controlled ovarian stimulation with gonadotropins~* Women with three or more controlled ovarian stimulation cycles

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 37 Years
- Healthy Volunteers: f

Study Arms:
- 5.2 µg (Type: EXPERIMENTAL): None
- 6.9 µg (Type: EXPERIMENTAL): None
- 8.6 µg (Type: EXPERIMENTAL): None
- 10.3 µg (Type: EXPERIMENTAL): None
- 12.1 µg (Type: EXPERIMENTAL): None
- 11 µg FbM (150 IU) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with cirrhosis without HCC in all liver function classes already receiving specific therapy for cirrhosis who accept be subjected to liver biopsy and to sign the written informed consent to participate to the study~* Patients with cirrhosis with multifocal HCC and clinical and/or radiological signs of persistence or recurrence of HCC in presence or absence of thrombosis of the portal vein, with a single nodule of \> 6 cm in size or multiple nodules of \> 3 cm in size who accept be subjected to liver biopsy and to sign the written informed consent to participate to the study~Exclusion Criteria:~* Age \< 18 yrs or \> 75 yrs~* Pregnancy or lactation~* Intolerance to somatostatin analogues~Treatment protocol:~* In all patients fulfilling the inclusion criteria, treatment will begin with octreotide-LAR at a dose of 30 mg every 28 days or lanreotide autogel 120 mg every 28 days for 3 months.~* After 28, 56 and 74 days (immediately before the next injection) all patients will be admitted to the Day Hospital of the IX Division of Internal Medicine of the D. Cotugno Hospital for the clinical examination, blood chemistry, blood sampling for the IGF axis analysis, and abdominal ultrasound. After 74 days, abdominal CT or MRI will also be performed.~* Then, in all survivors the interval between injection will be reduced to 21 days and follow up for the next 3 months will be done as stated before the day immediately preceding the injection.~* Then, in the subsequent follow-up the interval between injection will be reduced to 14 days and all procedures will be repeated at monthly intervals.~* All the patients fulfilling the inclusion criteria but refusing to participate to the study will be followed with the same methodology of those receiving the somatostatin analogues treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): 1. Patients with cirrhosis without HCC in all liver function classes already receiving specific therapy for cirrhosis who accept be subjected to liver biopsy and to sign the written informed consent to participate to the study~2. Patients with cirrhosis with multifocal HCC and clinical and/or radiological signs of persistence or recurrence of HCC in presence or absence of trombosis of the portal vein, with a single nodule of \>6 cm in size or multiple nodules of \>3 cm in size who accept be subjected to liver biopsy and to sign the written informed consent to participate to the study
- B (Type: OTHER): Historical controls

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Radiesse® Dermal Filler for Hand Rejuvenation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Has right and left hands with a rating of 3 or 4 on the Busso Hand Volume Severity Scale (BHVSS) as determined by the treating physician~* Signs a written informed consent~* Understands and accepts the obligation not to receive any other procedures in the dorsum of the hands through 12 month follow up~* Understands and accepts the obligation and is logistically able to present for all scheduled follow-up visits~Exclusion Criteria~* Has history of hypertropic scarring~* Has a known bleeding disorder or receiving medication that will increase the risk of bleeding as the result of injection~* Has a known hypersensitivity to any of the components of Radiesse or local anesthesia~* Has used predefined products or treatments on the dorsum of the hand within last 4 weeks or intends to use during study~* Has had any dermal fillers or surgery in the dorsum of the hand~* Is a female of child bearing potential and not using medically effective birth control or is pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Radiesse Injectable Dermal Filler (Type: EXPERIMENTAL): Device: Radiesse Injectable Dermal Filler
- Delayed Treatment (Type: ACTIVE_COMPARATOR): Cross over to treatment with Radiesse Injectable Dermal Filler at 3 Months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of primary myelofibrosis (PMF) according to the revised WHO criteria; or post-essential thrombocythemia-myelofibrosis (PET-MF) or post-polycythemia vera-myelofibrosis (PPV-MF) according to the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria.~* Dynamic International Prognostic Scoring System (DIPSS) intermediate-2 or highrisk MF.~* Measurable splenomegaly prior to study entry as demonstrated by palpable spleen measuring ≥ 5 cm below the left costal margin OR spleen volume of ≥ 450 cm\^3 measured by magnetic resonance imaging (MRI).~* Active symptoms of MF as demonstrated by a symptom score of at least 5 points (on a 0 to 10 scale) on at least one of the symptoms or a score of 3 or greater on at least 2 of the symptoms.~* Documented progressive disease during or after Janus kinase (JAK) inhibitor therapy.~* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.~Exclusion Criteria:~* Peripheral blood blast count of ≥ 10% or bone marrow blast count of ≥ 10%.~* Prior treatment with imetelstat.~* Any chemotherapy or MF-directed therapy, investigational drug, hydroxyurea, immunomodulatory or immunosuppressive therapy, corticosteroids or JAK inhibitor therapy ≤14 days prior to randomization.~* Major surgery within 4 weeks prior to randomization.~* Active systemic hepatitis infection requiring treatment (carriers of hepatitis virus are permitted to enter the study), of any type or known acute or chronic liver disease including cirrhosis.~* Prior history of hematopoietic stem cell transplant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imetelstat 4.7 mg/kg (Type: EXPERIMENTAL): None
- Imetelstat 9.4 mg/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopenia) Haematological Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. A diagnosis of MDS, AA, MF or thal based on currently recognized diagnostic criteria.~2. Explored or undergone established therapies eg haemopoietic stem cell transplant, immunosuppressive therapy, chemotherapy, growth factors, thalidomide, hypomethylating agent or androgens, and (a) are deemed not suitable, or (b) refuse or (c) have failed therapy~3. A preceding follow up period (without or with treatment) of 2-4 months as baseline (depending on the severity of cytopenia) before being enrolled into this study~4. Understand the trial nature of this treatment, agree to be compliant to medication, do not self medicate and have signed informed consent~5. Agreeable to regular blood tests and follow up marrow study as listed in schedule~Exclusion Criteria:~1. Life expectancy of shorter than one year~2. Significant organ failure including the following~3. Renal impairment with Cr above 200umol/L~4. Liver impairment with serum bilirubin \> 2x upper limits or transaminase \>3x upper limits~5. Escalation of treatment of introduction of new agents including growth factors, thalidomide, hypomethylating agents, immunosuppressive therapy or androgens once started on treatment with TCM is not allowed. Continuation of current therapy at same or lower doses is allowed~6. Women during pregnancy or lactation.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Treatment with Chinese herbal concoction (Type: EXPERIMENTAL): Patients must have a marrow study to confirm diagnosis of MDS, AA or MF. MDS is classified according to the WHO criteria and scored according to IPSS. The AA group is further classified into AA, SAA or VSAA . MF is defined by the Italian criteria and risk stratified by the Lilles Scoring system. Diagnosis of thal intermedia and major is based on previously done Hb electrophoresis and severity of disease is assessed by degree of anaemia.and frequency of blood transfusions~TCM diagnosis: Syndrome differentiation according to TCM theory will be assessed as a baseline by experienced TCM collaborators and classified into one of the few defined syndromes as follows~1. Yin deficiency of spleen and kidney~2. Yang deficiency of spleen and kidney~3. Deficiency of both Yin and Yang~4. Stagnation of dampness and poison in the blood~5. Excessive heat and poison

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Association of Hepatitis C Virus With Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Biopsy-proven invasive breast cancer.~Exclusion Criteria:~* Patients with unknown viral marker status.~* Patients who did not complete their management at OCMU.~* Patients with multiple cancer diagnoses.~* Patients with virus-unrelated hepatic pathology.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Study group (Type: None): The data of breast cancer patients treated at OCMU in the last 10 years will be retrieved from the hospital data filing system. All consecutive patients with biopsy-proven invasive breast cancer will be included.
- Control group (Type: None): A group of age-matched women from the same geographical distribution who are healthy volunteers or hospital patients without cancer diagnosis will serve as a control group for the HCV prevalence. We aim at a sample size with a study-to-control ratio of 1:3.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Intensity - Apraxia of Speech

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Veterans and non Veterans~* Males or females~* Stroke survivor who is at least 4 months post-stroke~* Speaker of English since childhood~* Ability to pass a pure-tone hearing screening (aided or unaided)~* currently non-hospitalized~* Age 21 to 90 years~Exclusion Criteria:~* neurological condition other than stroke~* currently clinically depressed~* history of speech/language problems prior to stroke~* untreated psychopathology

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- SPT - Intense First (Type: EXPERIMENTAL): Participants will receive intense application in the first phase of treatment, followed by the non intense application of treatment.
- SPT - Traditional First (Type: EXPERIMENTAL): Participants will receive non intense, traditional application of treatment in the first phase of treatment, followed by the intense application of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Mental Imagery Training on Brain Plasticity and Motor Function in Individuals With Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a diagnosis of idiopathic PD defined according to the UK Brain Bank diagnostic criteria and on a stable dopaminergic medication regimen will be included.~Exclusion Criteria:~* Age \< 40 years~* Non-English speaking~* Pregnancy~* Breastfeeding~* Excessive alcohol consumption (\> 7 drinks per week for women, \> 14 drinks per week for men) or substance use~* History of a neurological disorder such as a brain tumor, stroke, central nervous system infection, multiple sclerosis, movement disorder (other than PD), or seizures~* History of schizophrenia, bipolar disorder, attention deficit disorder, or obsessive compulsive disorder~* History of head injury with loss of consciousness~* Metallic surgical implants or traumatically implanted metallic foreign bodies~* Inability to lie flat for about an hour~* Discomfort being in small, enclosed spaces~* Dementia (Montreal Cognitive Assessment score \< 21)~* Depression (Beck Depression Inventory-II score \> 19)~* Hoehn \& Yahr stage \> 3 (i.e., able to stand and walk, but not fully independent)~* Focal neurological findings on exam that suggest cerebral pathology other than that associated with parkinsonism~* Motor symptoms that could potentially introduce too much motion artifact in the imaging data (e.g., MDS-UPDRS resting tremor score \> 1 in limbs, head/chin tremor, or dyskinesia by history or exam).

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with PD neurofeedback training (Type: EXPERIMENTAL): Patients will receive neurofeedback training.
- Patients with PD control (Type: ACTIVE_COMPARATOR): Patients will not receive neurofeedback training.
- Patients with PD (Type: NO_INTERVENTION): Patients perform mental imagery (motor and visual aspects combined) in the MRI scanner without neurofeedback training.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: WallFlex Biliary Fully Covered (FC) Chronic Pancreatitis Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Willing and able to comply with the study procedures and provide written informed consent to participate in the study~* Chronic pancreatitis~* Symptomatic bile duct stricture (defined by cholangitis or persistent jaundice for at least one month or cholestasis associated with at least 3 times normal alkaline phosphatase levels) documented at time of enrollment for naïve stricture or at the time of prior plastic stent placement in strictures that had one prior plastic stent inserted.12~* Common bile duct stricture based on imaging assessment of dilatation of the common and/or intrahepatic bile ducts~Exclusion Criteria:~* Biliary stricture of benign etiology other than chronic pancreatitis~* Prior biliary metal stent or any plastic stenting other than one plastic stent of 10 Fr or less for 6 months or fewer~* Developing obstructive biliary symptoms associated with an attack of acute pancreatitis~* Biliary stricture of malignant etiology~* Stricture within 2 cm of common bile duct bifurcation~* Known bile duct fistula or leak~* Subjects for whom endoscopic techniques are contraindicated~* Known sensitivity to any components of the stent or delivery system~* Symptomatic duodenal stenosis (with gastric stasis)~* Participation in another investigational study within 90 days prior to consent~* Investigator Discretion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Metal stents (Type: ACTIVE_COMPARATOR): The WallFlex Biliary Fully Covered Stent System is being evaluated for treatment of benign biliary strictures secondary to chronic pancreatitis.
- Plastic Stents (Type: ACTIVE_COMPARATOR): Plastic stents per Investigator preference are being evaluated for treatment of benign biliary strictures secondary to chronic pancreatitis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete